Challenges in validation of combination treatment strategies for CRC using patient-derived organoids

Area of Science:

• Oncology
• Translational Medicine
• Biotechnology

Background:

• Patient-derived organoids (PDOs) are established ex vivo models derived from patient tumors.
• PDOs exhibit phenotypic and genotypic similarity to the original tumor, complementing other cancer models.
• The predictive potential of PDOs for combination therapy response is not fully understood.

Purpose of the Study:

• To review the application of PDOs in validating and optimizing multi-drug combinations for personalized colorectal cancer (CRC) treatment.
• To discuss advancements in creating more complex PDO models by incorporating diverse cell types.
• To explore how advanced PDOs contribute to personalized medicine, especially in immunotherapy.

Main Methods:

• Review of existing literature on patient-derived organoids in cancer research.
• Analysis of recent advancements in PDO model development and cell type enrichment.
• Discussion of PDO applications in combination therapy and immunotherapy for CRC.

Main Results:

• PDOs show promise in screening and validating cancer drug candidates.
• Enriching PDOs with diverse cell types improves their in vivo mimicry.
• PDOs are increasingly used to predict sensitivity to combination therapies.

Conclusions:

• Patient-derived organoids are crucial for advancing personalized medicine in CRC.
• Sophisticated PDO models are narrowing the gap towards effective immunotherapy strategies.
• Further research is needed to overcome challenges and fully realize the potential of PDOs.